drugset / Trial / NCT06858319
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2031-06-25
- Completion
- 2031-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zigakibart | Monoclonal antibody | — | Subcutaneous |